Evidence map›Paper›PMID 35862673›Full record

ArticleJournal of virology2022

Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope.

Annette N Ratcliff, Colin M Venner, Abayomi S Olabode, Jason Knapp, Joshua Pankrac, Iulian Derecichei, Richard M Gibson, Andrés Finzi, Yue Li, Jamie F S Mann and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. SHIV fights back to evade destruction by eCD4-Ig but not without suffering debilitating wounds.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Annette N RatcliffDepartment of Molecular Biology and Microbiology and Division of Infectious Diseases, Case Western Reserve Universitygrid.67105.35, Cleveland, Ohio, USA.
Colin M VennerDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.
Abayomi S OlabodeDepartment of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada.
Jason KnappDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.
Joshua PankracDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.
Iulian DerecicheiDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.
Richard M GibsonImPaKT Facility, University of Western Ontario, London, Ontario, Canada.
Andrés FinziDépartement de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada.ORCID 0000-0002-4992-5288
Yue LiDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.
Jamie F S MannDepartment of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada.
Eric J ArtsDepartment of Molecular Biology and Microbiology and Division of Infectious Diseases, Case Western Reserve Universitygrid.67105.35, Cleveland, Ohio, USA.ORCID 0000-0002-4880-7968
Western University · CACase Western Reserve University · USUniversité de Montréal · CA

Funding

WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
Impact of HIV-1 Fitness on Disease ProgressionR01AI049170 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI ARTS, ERIC J · 2002 to 2024
$6.8M
Gouvernement du Canada | Canadian Institutes of Health Research (IRSC) 165802Gouvernement du Canada | Canadian Institutes of Health Research (IRSC) 377790HHS | National Institutes of Health (NIH) AI49170NIAID NIH HHS P30 AI036219NIAID NIH HHS R01 AI049170
6 · The paper itself

Abstract

A rare but natural polymorphism in the HIV-1 envelope (Env) glycoprotein, lysine at position 425 was selected as a mutation conferring resistance to maraviroc (MVC)

Indexed as

HIV-1HIV Envelope Protein gp120Virus InternalizationAntibodies, NeutralizingBinding SitesCD4 AntigensDrug Resistance, ViralHIV AntibodiesHumansMaravirocPolymorphism, GeneticProtein BindingAntibodies, NeutralizingCD4 AntigensHIV AntibodiesHIV Envelope Protein gp120MaravirocCD4 bindingentryHIVneutralizing antibodies

Identifiers

PMID35862673
PMCPMC9327689
OpenAlexW4283806236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.